Myh deficiency enhances intestinal tumorigenesis in multiple intestinal neoplasia (ApcMin/+) mice

Cancer Research

Volumn 64, Issue 24, 2004, Pages 8876-8881

  Sieber, Oliver M ^a   Howarth, Kimberley M ^a   Thirlwell, Christina ^a   Rowan, Andrew ^a   Mandir, Nikki ^a   Goodlad, Robert A ^a   Gilkar, Ashfaq ^a   Spencer Dene, Bradley ^a   Stamp, Gordon ^a   Johnson, Victoria ^b   Silver, Andrew ^b   Yang, Hanjing ^c   Miller, Jeffrey H ^c   Ilyas, Mohammad ^d   Tomlinson, Ian P M ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b ST MARK S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; GENE PRODUCT;

ABERRANT CRYPT FOCI; ADENOMATOUS POLYP; ALLELE LOSS; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST TUMOR; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CODON; COLON ADENOMA; COLORECTAL CARCINOMA; CONTROLLED STUDY; EXCISION REPAIR; GENE; GENE LOSS; GENE MUTATION; GERM LINE; HETEROZYGOSITY; HOMOZYGOSITY; INTESTINE CRYPT; INTESTINE TUMOR; INTRAGENIC MUTATION; MOUSE; MULTIPLE CANCER; MULTIPLE INTESTINE NEOPLASIA; MYH GENE; NONHUMAN; NUCLEIC ACID BASE SUBSTITUTION; PHENOTYPE; PRIORITY JOURNAL; RECTUM ADENOMA; SOMATIC MUTATION; TERMINATION CODON; TUMOR SUPPRESSOR GENE;

ADENOMA; ALLELES; ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; DNA GLYCOSYLASES; FEMALE; GENES, APC; INTESTINAL NEOPLASMS; INTESTINE, SMALL; LOSS OF HETEROZYGOSITY; MALE; MICE; MICE, INBRED C57BL; MUTATION; PRECANCEROUS CONDITIONS;

EID: 10844274799     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-2958     Document Type: Article

References (44)

1. Sieber OM, Tomlinson IP, Lamlum H. The adenomatous polyposis coli (APC) tumour suppressor - genetics, function and disease. Mol Med Today 2000;6:462-9.
2. Fearnhead NS, Britton MP, Bodmer WF. The ABC of APC. Hum Mol Genet 2001;10:721-33.
3. Sampson JR, Dolwani S, Jones S, et al. Autosomal recessive colorectal adenomatous polyposis due to inherited mutations of MYH. Lancet 2003;362:39-41.
4. Sieber OM, Lipton L, Crabtree M, et al. Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. N Engl J Med 2003;348: 791-9.
5. Enholm S, Hienonen T, Suomalainen A, et al. Proportion and phenotype of MYH-associated colorectal neoplasia in a population-based series of Finnish colorectal cancer patients. Am J Pathol. 2003;163:827-32.
6. Al-Tassan N, Chmiel NH, Maynard J, et al. Inherited variants of MYH associated with somatic G:C→A mutations in colorectal tumors. Nat Genet 2002;30:227-32.
7. Mo JY, Maki H, Sekiguchi M. Hydrolytic elimination of a mutagenic nucleotide, 8-oxodGTP, by human 18-kilodalton protein: sanitization of nucleotide pool. Proc Natl Acad Sci USA 1992;89:11021-5.
8. Sakumi K, Furuichi M, Tsuzuki T, et al. Cloning and expression of cDNA for a human enzyme that hydrolyzes 8-oxo- dGTP, a mutagenic substrate for DNA synthesis. J Biol Chem 1993;268:23524-30.
9. Oda H, Nakabeppu Y, Furuichi M, et al. Regulation of expression of the human MTH1 gene encoding 8-oxo-dGTPase. Alternative splicing of transcription products. J Biol Chem 1997;272:17843-50.
10. Lu R, Nash HM, Vereine GL. A mammalian DNA repair enzyme that excises oxidatively damaged guanines maps to a locus frequently lost in lung cancer. Curr Biol 1997;7:397-407.
11. Radicella JP, Dherin C, Desmaze C, et al. Cloning and characterization of hOGG 1, a human homolog of the OGG1 gene of Saccharomyces cerevisiae. Proc Natl Acad Sci USA 1997;94:8010-5.
12. Roldan-Arjona T, Wei YF, Carter KC, et al. Molecular cloning and functional expression of a human cDNA encoding the antimutator enzyme 8-hydroxyguanine-DNA glycosylase. Proc Natl Acad Sci USA 1997;94:8016-20.
13. Shinmura K, Kasai H, Sasaki A, et al. 8-hydroxyguanine (7,8-dihydro-8-oxoguanine) DNA glycosylase and AP lyase activities of hOGG1 protein and their substrate specificity. Mutat Res 1997;385:75-82.
14. Slupska MM, Baikalov C, Luther WM, et al. Cloning and sequencing a human homolog (hMYH) of the Escherichia coli mutY gene whose function is required for the repair of oxidative DNA damage. J Bacteriol 1996;178:3885-92.
15. Slupska MM, Luther WM, Chiang JH, et al. Functional expression of hMYH, a human homolog of the Escherichia coli MutY protein. J Bacteriol 1999;181:6210-3.
16. Takao M, Zhang QM, Yonei S, et al. Differential subcellular localization of human MutY homolog (hMYH) and the functional activity of adenine:8-oxoguanine DNA glycosylase. Nucleic Acids Res 1999;27:3638-44.
17. Jones S, Emmerson P, Maynard J, et al. Biallelic germline mutations in MYH predispose to multiple colorectal adenoma and somatic G:C→T:A mutations. Hum Mol Genet 2002;11:2961-7.
18. Lipton L, Halford SE, Johnson V, et al. Carcinogenesis in MYH-associated polyposis follows a distinct genetic pathway. Cancer Res 2003;63:7595-9.
19. Xie Y, Yang H, Cunanan C, et al. Deficiencies in mouse Myh and Ogg1 result in tumor predisposition and G to T mutations in codon 12 of the K-ras oncogene in lung tumors. Cancer Res 2004;64:3096-102.
20. Russo MT, De Luca G, Degan P, et al. Accumulation of the oxidative base lesion 8-hydroxyguanine in DNA of tumor-prone mice defective in both the Myh and Ogg1 DNA glycosylases. Cancer Res 2004;64:4411-4.
21. Shoemaker AR, Gould KA, Luongo C, et al. Studies of neoplasia in the Min mouse. Biochim Biophys Acta 1997;1332:F25-48.
22. Wilding J, Straub J, Bee J, et al. Cyclin D1 is not an essential target of beta-catenin signaling during intestinal tumorigenesis, but it may act as a modifier of disease severity in multiple intestinal neoplasia (Min) mice. Cancer Res 2002;62:4562-5.
23. Shoemaker AR, Moser AR, Dove WF. N-ethyl-N-nitrosourea treatment of multiple intestinal neoplasia (Min) mice: age-related effects on the formation of intestinal adenomas, cystic crypts, and epidermoid cysts. Cancer Res 1995;55:4479-85.
24. Shoemaker AR, Haigis KM, Baker SM, et al. Mlh1 deficiency enhances several phenotypes of Apc(Min)/+ mice. Oncogene 2000;19:2774-9.
25. Paulsen JE, Namork E, Steffensen IL, et al. Identification and quantification of aberrant crypt foci in the colon of Min mice-a murine model of familial adenomatous polyposis. Scand J Gastroenterol 2000;35:534-9.
26. Paulsen JE, Steffensen IL, Loberg EM, et al. Qualitative and quantitative relationship between dysplastic aberrant crypt foci and tumorigenesis in the Min/+ mouse colon. Cancer Res 2001;61:5010-5.
27. Yamada Y, Hata K, Hirose Y, et al. Microadenomatous lesions involving loss of Apc heterozygosity in the colon of adult Apc(Min/+) mice. Cancer Res 2002;62:6367-70.
28. Bird RP. Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings. Cancer Lett 1987;37:147-51.
29. Wargovich MJ, Jimenez A, McKee K, et al. Efficacy of potential chemopreventive agents on rat colon aberrant crypt formation and progression. Carcinogenesis (Lond) 2000;21:1149-55.
30. Levy DB, Smith KJ, Beazer-Barclay Y, et al. Inactivation of both APC alleles in human and mouse tumors. Cancer Res 1994;54:5953-8.
31. Luongo C, Moser AR, Gledhill S, et al. Loss of Apc+ in intestinal adenomas from Min mice. Cancer Res 1994;54:5947-52.
32. Bos JL. The ras gene family and human Carcinogenesis. Mutat Res 1988;195:255-71.
33. Forrester K, Almoguera C, Han K, et al. Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. Nature (Lond) 1987;327:298-303.
34. Lamlum H, Papadopoulou A, Ilyas M, et al. APC mutations are sufficient for the growth of early colorectal adenomas. Proc Natl Acad Sci USA 2000;97:2225-28.
35. Smits R, Kartheuser A, Jagmohan-Changur S, et al. Loss of Apc and the entire chromosome 18 but absence of mutations at the Ras and Tp53 genes in intestinal tumors from Apc1638N, a mouse model for Apc-driven carcinogenesis. Carcinogenesis (Lond) 1997;18:321-7.
36. Kambara T, Whitehall VL, Spring KJ, et al. Role of inherited defects of MYH in the development of sporadic colorectal cancer. Genes Chromosomes Cancer 2004;40: 1-9.
37. Wong E, Yang K, Kuraguchi M, et al. Mbd4 inactivation increases C→T transition mutations and promotes gastrointestinal tumor formation. Proc Natl Acad Sci USA 2002;99:14937-42.
38. Reitmair AH, Cai JC, Bjerknes M, et al. MSH2 deficiency contributes to accelerated APC-mediated intestinal tumorigenesis. Cancer Res 1996;56:2922-6.
39. Baker SM, Harris AC, Tsao JL, et al. Enhanced intestinal adenomatous polyp formation in Pms2-/-;Min mice. Cancer Res 1998;58:1087-9.
40. Smits R, Hofland N, Edelmann W, et al. Somatic Apc mutations are selected upon their capacity to inactivate the beta-catenin downregulating activity. Genes Chromosomes Cancer 2000;29:229-39.
41. Sohn KJ, Choi M, Song J, et al. Msh2 deficiency enhances somatic Apc and p53 mutations in Apc+/-Msh2-/- mice. Carcinogenesis (Lond) 2003;24:217-24.
42. Merritt AJ, Gould KA, Dove WF. Polyclonal structure of intestinal adenomas in ApcMin/+ mice with concomitant loss of Apc+ from all tumor lineages. Proc Natl Acad Sci USA 1997;94:13927-31.
43. Halford SE, Rowan AJ, Lipton L, et al. Germline mutations but not somatic changes at the MYH locus contribute to the pathogenesis of unselected colorectal cancers. Am J Pathol. 2003;162:1545-8.
44. Shoemaker AR, Moser AR, Midgley CA, et al. A resistant genetic background leading to incomplete penetrance of intestinal neoplasia and reduced loss of heterozygosity in ApcMin/+ mice. Proc Natl Acad Sci USA 1998;95:10826-31.